| Name | Title | Contact Details |
|---|---|---|
Sandra Eayrs |
Vice President of Human Resources | Profile |
CooperSurgical is the leading company dedicated to providing medical devices and procedure solutions that improve health care delivery to women regardless of clinical setting. Our company is fostering that position through expansion of its core
Headquartered in Milford, Massachusetts, RenalGuard Solutions, Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Our newest product, RenalGuard®, has been developed to help prevent the onset of contrast-induced nephropathy (CIN) in at-risk patients undergoing certain imaging procedures. It is already approved for sale in the EU for general fluid balancing. Two investigator-sponsored European studies have demonstrated RenalGuard`s effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by the FDA. The RenalGuard System™ consists of a closed loop, software-controlled console and single-use sets that physicians and nurses use for automated matched fluid replacement to minimize over- or under-hydration of patients during medical procedures where creating and maintaining high urine outputs is beneficial.
Cygnus Inc is a Petoskey, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Build a portfolio of market-leading medical device companies comprised of FDA approved, high revenue-generating technologies and products from the largest market opportunity segments and emerging research and development technologies. Build a portfolio of market-leading medical device companies comprised of FDA approved, high revenue-generating technologies and products from the largest market opportunity segments and emerging research and development technologies.
Enabling surgeons with clinically-relevant, innovative fluorescence imaging solutions to enhance the lives of patients and their surgeons, while reducing health care costs, is Novadaq’s global mission. SPY fluorescence imaging technology provides surgeons with real-time visualization, leading to improved outcomes and reduced costs without exposing the patient to harmful ionizing radiation or contrast dye toxicity. More than 130 peer-reviewed publications demonstrate that the use of SPY during complex surgery, leads to fewer post-operative complications and lower hospital costs. The SPY Imaging System is United States Food and Drug Administration (“FDA”) 510(k) cleared for use in seven surgical specialties. The endoscopic version of SPY called PINPOINT®, combines the capabilities of SPY Imaging with high definition (“HD”) visible light visualization offered by conventional endoscopes. Our unique business model of partnering with market-leading companies to drive adoption of our fluorescence imaging technology, while building our own commercial infrastructure is the cornerstone of our corporate strategy for growth.